Medtronic plc filed an 8-K press release on November 17, 2026, announcing that the U.S. Food and Drug Administration cleared its Hugo robotic-assisted surgery system for use in general surgery procedures in the United States.
Key Highlights
- FDA clearance scope: The clearance covers upper abdominal procedures including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia, and small bowel resection, as well as lower abdominal procedures of inguinal hernia and appendectomy, according to the filing.
- Procedure volume: The company disclosed that the cleared procedures account for approximately 3.5 million surgeries annually in the U.S., representing more than half of all soft-tissue procedures performed in the country each year.
- Global procedure growth: According to the filing, Hugo RAS system procedure growth globally is running at more than two times the robotic surgery market and is on track to surpass 50,000 procedures by the end of the Medtronic fiscal year.
- U.S. expansion: The filing states the clearance extends the Hugo RAS system's U.S. indication beyond urology, where it had previously been cleared for use.
- Instrument integration: The company noted that the LigaSure RAS Maryland instrument, used in more than 45 million open and laparoscopic procedures, is compatible with the Hugo RAS system.
- General surgery growth outside the U.S.: The filing reported that general surgery represents the highest growth category for Hugo RAS system procedures outside the U.S., surpassing urology and gynecology.
Hugo RAS System's U.S. General Surgery Expansion: What the Filing Describes
Medtronic plc (NYSE:MDT), headquartered in Galway, Ireland, announced in the filing that the FDA cleared the Hugo robotic-assisted surgery system for general surgery use in the United States. The company disclosed that the clearance covers both upper and lower abdominal procedures, citing cholecystectomy, Roux-en-Y gastric bypass, ventral hernia, small bowel resection, inguinal hernia, and appendectomy as specific examples included under the cleared indications.
According to the filing, the Hugo RAS system features a modular design that allows surgical teams to use only the robotic arms needed for a given procedure, while an open console is described as connecting the surgeon with the operating room team and patient. The company stated the LigaSure RAS Maryland instrument, a vessel-sealing technology with a history in open and laparoscopic procedures, is available for use with the Hugo system in these cases. Matt Anderson, identified in the filing as senior vice president and president of Medtronic's Surgical business, is quoted stating that "Hugo expands choice with a practical option to help hospitals address capacity and access challenges."
The filing also includes a statement from Dr. Francesco Bianco, identified as a UI Health surgeon and professor of surgery at the University of Illinois College of Medicine, referencing the system's use at that academic health system. Medtronic noted the Hugo RAS system is currently in clinical use "at a growing number of health systems and hospitals across the U.S." The company also disclosed that it is the sole authorized distributor of Cornerstone Robotic's Sentire surgical system outside of the United States. The filing notes that any forward-looking statements are subject to risks and uncertainties described in Medtronic's periodic reports on file with the Securities and Exchange Commission, and that "actual results may differ materially from anticipated results."
What Was Disclosed
Medtronic announced FDA clearance of its Hugo RAS system for U.S. general surgery procedures, expanding its indicated use beyond urology. The cleared procedures collectively represent approximately 3.5 million annual U.S. surgeries, according to the filing.





Please wait processing your request...